RU2007147609A - Составы для эффективной потери веса - Google Patents
Составы для эффективной потери веса Download PDFInfo
- Publication number
- RU2007147609A RU2007147609A RU2007147609/15A RU2007147609A RU2007147609A RU 2007147609 A RU2007147609 A RU 2007147609A RU 2007147609/15 A RU2007147609/15 A RU 2007147609/15A RU 2007147609 A RU2007147609 A RU 2007147609A RU 2007147609 A RU2007147609 A RU 2007147609A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- derivative
- group
- agonist
- norepinephrine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 17
- 230000004580 weight loss Effects 0.000 title claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 52
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract 25
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract 19
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims abstract 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract 12
- 229960002748 norepinephrine Drugs 0.000 claims abstract 12
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims abstract 12
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims abstract 12
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims abstract 12
- 239000000952 serotonin receptor agonist Substances 0.000 claims abstract 12
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims abstract 10
- 229960001058 bupropion Drugs 0.000 claims abstract 10
- 239000003112 inhibitor Substances 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 9
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 claims abstract 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 7
- 125000000962 organic group Chemical group 0.000 claims abstract 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000000556 agonist Substances 0.000 claims abstract 6
- 239000005557 antagonist Substances 0.000 claims abstract 6
- 230000001773 anti-convulsant effect Effects 0.000 claims abstract 6
- 239000001961 anticonvulsive agent Substances 0.000 claims abstract 6
- 229960003965 antiepileptics Drugs 0.000 claims abstract 6
- 229960003638 dopamine Drugs 0.000 claims abstract 6
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract 6
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims abstract 6
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims abstract 6
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims abstract 5
- 229940098788 GABA receptor antagonist Drugs 0.000 claims abstract 5
- -1 venlafactin Chemical compound 0.000 claims 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 4
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 3
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 3
- 229960002767 ethosuximide Drugs 0.000 claims 3
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 2
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims 2
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 2
- 229960002133 almotriptan Drugs 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960002802 bromocriptine Drugs 0.000 claims 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 2
- 229960000623 carbamazepine Drugs 0.000 claims 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 2
- 229960001653 citalopram Drugs 0.000 claims 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 2
- 229960003120 clonazepam Drugs 0.000 claims 2
- 229960004362 clorazepate Drugs 0.000 claims 2
- XDDJGVMJFWAHJX-UHFFFAOYSA-M clorazepic acid anion Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-M 0.000 claims 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004890 diethylpropion Drugs 0.000 claims 2
- 229960002866 duloxetine Drugs 0.000 claims 2
- 229960004341 escitalopram Drugs 0.000 claims 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 2
- 229960003472 felbamate Drugs 0.000 claims 2
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- 229960004038 fluvoxamine Drugs 0.000 claims 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 2
- 229960000693 fosphenytoin Drugs 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- 229960004002 levetiracetam Drugs 0.000 claims 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 2
- 229960003587 lisuride Drugs 0.000 claims 2
- 229960004391 lorazepam Drugs 0.000 claims 2
- 229960005254 naratriptan Drugs 0.000 claims 2
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims 2
- 229940105631 nembutal Drugs 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004851 pergolide Drugs 0.000 claims 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 2
- 229960003562 phentermine Drugs 0.000 claims 2
- 229960002036 phenytoin Drugs 0.000 claims 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 2
- 229960003089 pramipexole Drugs 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 2
- 229960003770 reboxetine Drugs 0.000 claims 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 2
- 229960001879 ropinirole Drugs 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 2
- 229960004425 sibutramine Drugs 0.000 claims 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 2
- 229960003708 sumatriptan Drugs 0.000 claims 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims 2
- 229960004394 topiramate Drugs 0.000 claims 2
- 229940102566 valproate Drugs 0.000 claims 2
- 229960002911 zonisamide Drugs 0.000 claims 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims 1
- 229960002837 benzphetamine Drugs 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002284 frovatriptan Drugs 0.000 claims 1
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- NDVZIUGCCMZHLG-UHFFFAOYSA-N n-methyl-3-(2-methylsulfanylphenoxy)-3-phenylpropan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1SC NDVZIUGCCMZHLG-UHFFFAOYSA-N 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 229960000436 phendimetrazine Drugs 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229960000425 rizatriptan Drugs 0.000 claims 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims 1
- 229910018830 PO3H Inorganic materials 0.000 abstract 2
- 0 *OC(CCC1(C23CCN(CC4CC4)C1C1)O)C2Oc2c3c1ccc2O* Chemical compound *OC(CCC1(C23CCN(CC4CC4)C1C1)O)C2Oc2c3c1ccc2O* 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N CC(Oc1ccccc1)=O Chemical compound CC(Oc1ccccc1)=O IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70287705P | 2005-07-27 | 2005-07-27 | |
| US60/702,877 | 2005-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007147609A true RU2007147609A (ru) | 2009-09-10 |
Family
ID=37198787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007147609/15A RU2007147609A (ru) | 2005-07-27 | 2006-07-24 | Составы для эффективной потери веса |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070117827A1 (https=) |
| EP (1) | EP1907005A1 (https=) |
| JP (1) | JP2009502931A (https=) |
| KR (1) | KR20080042092A (https=) |
| CN (1) | CN101237886A (https=) |
| AU (1) | AU2006275914A1 (https=) |
| BR (1) | BRPI0613911A2 (https=) |
| CA (1) | CA2614539A1 (https=) |
| IL (1) | IL188442A0 (https=) |
| MX (1) | MX2008001136A (https=) |
| RU (1) | RU2007147609A (https=) |
| WO (1) | WO2007016108A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| HUE034290T2 (en) | 2003-04-29 | 2018-02-28 | Orexigen Therapeutics Inc | Preparations containing opioid antagonist and bupropion to affect weight loss |
| CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| TWI609702B (zh) | 2006-11-09 | 2018-01-01 | 歐瑞根治療有限公司 | 層狀醫藥調配物 |
| US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
| JP2011500686A (ja) | 2007-10-18 | 2011-01-06 | アイコ バイオテクノロジー | オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤 |
| WO2009143299A1 (en) | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Hepatoprotectant acetaminophen mutual prodrugs |
| JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| SMT201700232T1 (it) | 2010-12-03 | 2017-07-18 | Orexigen Therapeutics Inc | Aumento della biodisponibilita' farmacologica nella terapia con naltrexone |
| LT3730132T (lt) | 2012-06-06 | 2022-08-25 | Nalpropion Pharmaceuticals Llc | Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| GB201704909D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
| GB201704911D0 (en) | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | High dose combo I |
| WO2018178690A1 (en) * | 2017-03-28 | 2018-10-04 | LDN Pharma Limited | An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040024006A1 (en) * | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
| HUE034290T2 (en) * | 2003-04-29 | 2018-02-28 | Orexigen Therapeutics Inc | Preparations containing opioid antagonist and bupropion to affect weight loss |
-
2006
- 2006-07-24 US US11/492,685 patent/US20070117827A1/en not_active Abandoned
- 2006-07-24 CN CNA2006800271079A patent/CN101237886A/zh active Pending
- 2006-07-24 RU RU2007147609/15A patent/RU2007147609A/ru not_active Application Discontinuation
- 2006-07-24 AU AU2006275914A patent/AU2006275914A1/en not_active Abandoned
- 2006-07-24 CA CA002614539A patent/CA2614539A1/en not_active Abandoned
- 2006-07-24 KR KR1020087004150A patent/KR20080042092A/ko not_active Withdrawn
- 2006-07-24 WO PCT/US2006/028875 patent/WO2007016108A1/en not_active Ceased
- 2006-07-24 EP EP06800325A patent/EP1907005A1/en not_active Withdrawn
- 2006-07-24 JP JP2008524072A patent/JP2009502931A/ja active Pending
- 2006-07-24 BR BRPI0613911-6A patent/BRPI0613911A2/pt not_active Application Discontinuation
- 2006-07-24 MX MX2008001136A patent/MX2008001136A/es not_active Application Discontinuation
-
2007
- 2007-12-26 IL IL188442A patent/IL188442A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070117827A1 (en) | 2007-05-24 |
| WO2007016108B1 (en) | 2007-05-10 |
| KR20080042092A (ko) | 2008-05-14 |
| EP1907005A1 (en) | 2008-04-09 |
| BRPI0613911A2 (pt) | 2011-02-22 |
| CA2614539A1 (en) | 2007-02-08 |
| AU2006275914A1 (en) | 2007-02-08 |
| IL188442A0 (en) | 2008-04-13 |
| JP2009502931A (ja) | 2009-01-29 |
| CN101237886A (zh) | 2008-08-06 |
| MX2008001136A (es) | 2008-03-13 |
| WO2007016108A1 (en) | 2007-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007147609A (ru) | Составы для эффективной потери веса | |
| JP2009502931A5 (https=) | ||
| AP2001002307A0 (en) | B3 adrenergic receptor agonists and uses thereof. | |
| ES2252978T3 (es) | Agonistas 5ht2 serotonergicos para tratar el glaucoma. | |
| RU2007103313A (ru) | Комбинация бупропина и другого состава для эффективной потери веса | |
| JP4343948B2 (ja) | 体重減少に影響を及ぼすための組成物 | |
| RU96109832A (ru) | Синергическое лечение паркинсонизма | |
| RU2008135264A (ru) | Терапевтическое средство для воспалительных заболеваний кишечника, содержащее в качестве активного ингредиента производное 2-амино-1,3-пропандиола, или способ лечения воспалительных заболеваний кишечника | |
| EP1201678A4 (en) | BICYCLONUCLEOSID Analogs | |
| KR950032258A (ko) | 세포부착 저해제로서의 설페이트화 알파(α)-당지질 유도체 | |
| DOP2001000170A (es) | Derivados de tiofeno utiles como agentes anticancesoros | |
| CY1112911T1 (el) | Θεραπευτικος παραγοντας ηπατικης νοσου, που περιεχει παραγωγο 2-αμινο-1,3-προπανοδιολης ως δραστικο συστατικο | |
| TW200814988A (en) | Therapeutic combination for painful medical conditions | |
| JP2007508325A5 (https=) | ||
| HUP0202938A2 (hu) | N-aril-2-(szulfonil-amino)-benzamidok mint foszfát-transzport inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
| RU2004126093A (ru) | Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени | |
| YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
| PE20070521A1 (es) | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a | |
| DK1523486T3 (da) | Tetracykliske arylsulfonylindoler med serotoninreceptor-affinitet | |
| JP5371762B2 (ja) | ムスカリン性受容体ｍ１拮抗薬による肥満の処置 | |
| ZA200409887B (en) | Novel tetracyclic arylcarbonyl Indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | |
| Khairallah et al. | Potentiation of vascular myotropic responses by metanephrine and other noncatecholamines | |
| Kier et al. | Hallucinogenic Agents | |
| Rényi et al. | Effects of amiflamine and related compounds on the accumulation of biogenic monoamines in rat brain slices in vitro and ex vivo in relation to their behavioural effects | |
| Lebel et al. | Dopamine uptake inhibitory activity of novel tryptamine 5‐HT1 receptor ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110124 |